Skip to main content

TYVASO DPI IS NOW APPROVED

Learn more

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

SELECT INDICATION
Request a Rep

BREEZE STUDY

THE BREEZE STUDY WAS DESIGNED TO ASSESS THE SAFETY AND TOLERABILITY OF SWITCHING FROM TYVASO TO TYVASO DPI1

BREEZE Study Design: This open-label clinical study evaluated patients with PAH (N=51) who were on a stable dose of TYVASO and were switched to a corresponding dose of TYVASO DPI.1

Patients underwent safety and pharmacokinetic assessments and 6-minute walk tests, and also completed questionnaires about device preference and satisfaction.1

49 of 51 patients (96%) elected to continue therapy with TYVASO DPI in an optional extension phase (OEP) with follow-up visits every 8 weeks.1

SELECT PATIENT BACKGROUND INFORMATION

  • Patients started TYVASO ≥3 months prior to the baseline visit and were on a stable regimen (no change in dose within 30 days of baseline visit) of TYVASO (6 to 12 breaths QID)1
  • 80% of patients were on dual background therapy in addition to TYVASO1*
    • If receiving other approved background therapy, the patient was required to be on a stable dose with no additions or discontinuations for a minimum of 30 days1
  • 61% of patients were FC II at screening1†
  • FC IV patients were excluded from the study2
  • Patients had a mean baseline 6MWD of 418.9 m (SD 109.4)1
  • Patients had a forced expiratory volume in 1 second (FEV1) ≥60% and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio ≥60% during the 6 months prior to enrollment1

*84.3% endothelin receptor antagonist, 80.4% phosphodiesterase type 5 inhibitor, and 13.7% soluble guanylate cyclase stimulator.1

†12% were FC I and 27% were FC III.1

ADVERSE REACTIONS: CONSISTENT SAFETY AND TOLERABILITY WHEN SWITCHING TO TYVASO DPI3

During the 3-week treatment phase of the BREEZE study, most commonly reported (≥4% of patients) AEs in patients previously stable on TYVASO were1,3:

Adverse Event
Percentage
Cough
35%
Headache
16%
Dyspnea
8%
Nausea
6%

Discontinuation of TYVASO DPI due to an AE occurred in 2 (3.9%) patients.1

Patient tolerability, as assessed by incidence of new adverse events following transition to TYVASO DPI, was consistent with the expected known safety profile of TYVASO.3

SYSTEMIC EXPOSURE WAS SIMILAR BETWEEN TYVASO DPI AND TYVASO1,4

Mean treprostinil concentration over time (dose levels pooled)4

Chart showing the systemic exposure of TYVASO as compared to TYVASO DPI over time

The maximum mean treprostinil concentration occurred rapidly for both TYVASO and TYVASO DPI in the low-, mid-, and high-dose groups: 32 mcg (6-7 breaths; n=2), 48 mcg (8-10 breaths; n=27), and 64 mcg (11-12 breaths; n=22).1,2

ADDITIONAL IMPROVEMENT IN EFFICACY WITH TYVASO DPI1

11.5 m additional increase in 6MWD1

For patients previously stable on TYVASO, TYVASO DPI demonstrated a significant improvement in 6MWD at week 3 compared with TYVASO treatment at baseline. Interim results of the OEP suggest that this improvement was sustained over 51 weeks.1

Satisfaction with TYVASO DPI significantly improved when compared with TYVASO1

98%

45/46 (P<0.0001)

REPORTED PATIENT SATISFACTION WITH TYVASO DPI

at week 3 compared with 31% (16/51) of patients satisfied with the TYVASO ultrasonic nebulizer at baseline.1

SEE HOW TYVASO DPI IS DOSED AND TITRATED.

LEARN MORE